Reported muscle symptoms during statin treatment amongst Italian dyslipidaemic patients in the real-life setting: the PROSISA Study
- Creators
- Casula M.
- Gazzotti M.
- Bonaiti F.
- OImastroni E.
- Arca M.
- Averna M.
- Zambon A.
- Catapano A. L.
- Arca M.
- Montali A.
- Averna M.
- Giammanco A.
- Biolo G.
- Vinci P.
- Borghi C.
- D'Addato S.
- Bossi A. C.
- Meregalli G.
- Branchi A.
- Squiccimarro G.
- Cavalot F.
- Ramadori L.
- Cipollone F.
- Bucci M.
- Del Ben M.
- Angelico F.
- Fiorenza A. M.
- Colombo E.
- Grigore L.
- Zampoleri V.
- Lupattelli G.
- Gandolfo V.
- Mandraffino G.
- Savarino F.
- Mombelli G.
- Pavanello C.
- Pisciotta L.
- Pasta A.
- Purrello F.
- Scicali R.
- Rubba P.
- Fortunato G.
- Sabba C.
- Suppressa P.
- Sarzani R.
- Di Pentima C.
- Vigna G. B.
- Colangiulo A.
- Werba J. P.
- Vigo L. M.
- Zambon S.
- Previato L.
- Zenti M. G.
- Maneschi C.
- Others:
- Casula, M.
- Gazzotti, M.
- Bonaiti, F.
- Oimastroni, E.
- Arca, M.
- Averna, M.
- Zambon, A.
- Catapano, A. L.
- Arca, M.
- Montali, A.
- Averna, M.
- Giammanco, A.
- Biolo, G.
- Vinci, P.
- Borghi, C.
- D'Addato, S.
- Bossi, A. C.
- Meregalli, G.
- Branchi, A.
- Squiccimarro, G.
- Cavalot, F.
- Ramadori, L.
- Cipollone, F.
- Bucci, M.
- Del Ben, M.
- Angelico, F.
- Fiorenza, A. M.
- Colombo, E.
- Grigore, L.
- Zampoleri, V.
- Lupattelli, G.
- Gandolfo, V.
- Mandraffino, G.
- Savarino, F.
- Mombelli, G.
- Pavanello, C.
- Pisciotta, L.
- Pasta, A.
- Purrello, F.
- Scicali, R.
- Rubba, P.
- Fortunato, G.
- Sabba, C.
- Suppressa, P.
- Sarzani, R.
- Di Pentima, C.
- Vigna, G. B.
- Colangiulo, A.
- Werba, J. P.
- Vigo, L. M.
- Zambon, S.
- Previato, L.
- Zenti, M. G.
- Maneschi, C.
Description
Aim: Statin-associated muscle symptoms (SAMS) are a major determinant of poor treatment adherence and/or discontinuation, but a definitive diagnosis of SAMS is challenging. The PROSISA study was an observational retrospective study aimed to assess the prevalence of reported SAMS in a cohort of dyslipidaemic patients. Methods: Demographic/anamnestic data, biochemical values and occurrence of SAMS were collected by 23 Italian Lipid Clinics. Adjusted logistic regression was performed to estimate odds ratio (OR) and 95% confidence intervals for association between probability of reporting SAMS and several factors. Results: Analyses were carried out on 16 717 statin-treated patients (mean ± SD, age 60.5 ± 12.0 years; 52.1% men). During statin therapy, 9.6% (N = 1599) of patients reported SAMS. Women and physically active subjects were more likely to report SAMS (OR 1.23 [1.10–1.37] and OR 1.35 [1.14–1.60], respectively), whist age ≥ 65 (OR 0.79 [0.70–0.89]), presence of type 2 diabetes mellitus (OR 0.62 [0.51–0.74]), use of concomitant nonstatin lipid-lowering drugs (OR 0.87 [0.76–0.99]), use of high-intensity statins (OR 0.79 [0.69–0.90]) and use of potential interacting drugs (OR 0.63 [0.48–0.84]) were associated with lower probability of reporting SAMS. Amongst patients reporting SAMS, 82.2% underwent dechallenge (treatment interruption) and/or rechallenge (change or restart of statin therapy), with reappearance of muscular symptoms in 38.4% (3.01% of the whole cohort). Conclusions: The reported prevalence of SAMS was 9.6% of the whole PROSISA cohort, but only a third of patients still reported SAMS after dechallenge/rechallenge. These results emphasize the need for a better management of SAMS to implement a more accurate diagnosis and treatment re-evaluation.
Additional details
- URL
- http://hdl.handle.net/11567/1062789
- URN
- urn:oai:iris.unige.it:11567/1062789
- Origin repository
- UNIGE